Krystal Biotech, Inc. (KRYS) Stock Price & Analysis
Krystal Biotech, Inc. (KRYS) closed at USD 320.13 on Thursday, October 22, 2026, down 0.63% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 320.13; the Oct 22, 2026 session ranged USD 317.05–328.48 on volume of 245,198 shares. Market capitalization is —, with a 52-week range of USD 183.03–382.54 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:49 UTC.
Also available as compact Markdown for AI agents: nexqual.com/KRYS.md
Key facts (KRYS)
- Last four reported quarters (through Jun 30, 2026): revenue $440M, net income $241M (54.8% margin), free cash flow $258M (SEC filings).
- 1 of 80 tracked superinvestors hold KRYS (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 7 Form 4 filings, $42.1M; 1 not under a Rule 10b5-1 plan ($8.2M); 0 by opportunistic insiders, 4 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y +71.7% vs S&P 500 +14.9%; 5Y +489.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-02, EPS estimate USD 1.92, revenue estimate $127M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (KRYS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0K | $0K | $50.7M | $291M | $389M | $440M |
| Operating income | -$68.3M | -$145M | -$110M | $65.7M | $161M | $198M |
| Net income | -$69.6M | -$140M | $10.9M | $89.2M | $205M | $241M |
| EPS (diluted) | -$3.13 | -$5.49 | $0.39 | $3.00 | $6.84 | — |
| Free cash flow | -$116M | -$154M | -$101M | $119M | $189M | $258M |
| Operating margin | — | — | -216.2% | 22.6% | 41.5% | 44.9% |
| Net margin | — | — | 21.6% | 30.7% | 52.6% | 54.8% |
| Revenue growth | — | — | — | +473.0% | +33.9% | — |
| Cash + short-term investments | $438M | $379M | $532M | $598M | $828M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (KRYS)
P/E at fiscal year-ends: Dec 2025 36.0x, Dec 2024 52.3x, Dec 2023 314.9x.
Superinvestors (SEC 13F-HR, Q2 2026) (KRYS)
1 of 80 tracked investors hold KRYS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Torray Funds | 0.61% | $4.5M | Added +1.0% |
Insider sales (SEC Form 4, open-market, last ~7 months) (KRYS)
6 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Krishnan Suma | President, R&D | 25,000 | $9.0M | 1.6% | Yes (adopted September 4, 2025) | Routine (sold in Dec each year 2023–2025; this trade is outside those months) |
| 2026-09-04 | Krishnan Krish S | President and CEO | 25,000 | $9.0M | 1.6% | Yes (adopted September 4, 2025) | Routine (sold in Dec each year 2023–2025; this trade is outside those months) |
| 2026-08-14 | Rossi Dino A | Director | 25,000 | $8.2M | 33.3% | No | Too little history (no open-market trades in 2024 or 2025) |
| 2026-06-25 | Thomas John Charles | EVP, General Counsel | 1,000 | $347K | 100% | Yes (adopted February 23, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-04 | Krishnan Suma | President, R&D | 25,000 | $7.7M | 1.6% | Yes (adopted September 4, 2025) | Routine (sold in Dec each year 2023–2025; this trade is outside those months) |
| 2026-06-04 | Krishnan Krish S | President and CEO | 25,000 | $7.7M | 1.5% | Yes (adopted September 4, 2025) | Routine (sold in Dec each year 2023–2025; this trade is outside those months) |
| 2026-05-26 | Thomas John Charles | EVP, General Counsel | 642 | $194K | 100% | Yes (adopted February 23, 2026) | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (KRYS)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | HC Wainwright & Co. | Reiterated | Buy | $361 |
| 2026-09-21 | B of A Securities | Target raised | Buy | $392 → $400 |
| 2026-08-14 | RBC Capital | Initiated | Outperform | $400 |
| 2026-08-04 | Citigroup | Target raised | Buy | $378 → $386 |
| 2026-07-14 | B of A Securities | Target raised | Buy | $364 → $396 |
Total return (dividends reinvested) (KRYS)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +71.7% | +489.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +72.0% | +42.5% |
| Volatility (annualized) | 37.9% | 53.9% |
| Max drawdown | -17.3% (Jun 2026→Aug 2026) | -41.5% (Jul 2024→May 2025) |
KRYS revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $91.6M | 76.9% | -4.6% |
| Europe | $19.3M | 16.2% | — |
| Japan | $8.3M | 7.0% | — |
| Total revenue | $119.2M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
KRYS suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | TAKEDA PHARMACEUTICAL CO LTD (TAK) | “•Gene Silencing Approaches: We are aware of two companies, Takeda Pharmaceutical Company Limited (in partnership with Arrowhead Pharmaceutical Inc.) and Novo Nordisk A/S (in partnership with Alnylam Pharmaceuticals, Inc.), which are developing interfering RNA medicines to treat the liver manifestations of AATD.” |
| Partner | Arrowhead Pharmaceutical | “•Gene Silencing Approaches: We are aware of two companies, Takeda Pharmaceutical Company Limited (in partnership with Arrowhead Pharmaceutical Inc.) and Novo Nordisk A/S (in partnership with Alnylam Pharmaceuticals, Inc.), which are developing interfering RNA medicines to treat the liver manifestations of AATD.” |
| Partner | Novo Nordisk (NVO) | “•Gene Silencing Approaches: We are aware of two companies, Takeda Pharmaceutical Company Limited (in partnership with Arrowhead Pharmaceutical Inc.) and Novo Nordisk A/S (in partnership with Alnylam Pharmaceuticals, Inc.), which are developing interfering RNA medicines to treat the liver manifestations of AATD.” |
| Partner | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | “•Gene Silencing Approaches: We are aware of two companies, Takeda Pharmaceutical Company Limited (in partnership with Arrowhead Pharmaceutical Inc.) and Novo Nordisk A/S (in partnership with Alnylam Pharmaceuticals, Inc.), which are developing interfering RNA medicines to treat the liver manifestations of AATD.” |
Quoted from the company's 10-K filed Feb 17, 2026.
KRYS company outlook (results filed Aug 3, 2026)
- “Financial Guidance ($ in millions) FY 2026 Guidance Non-GAAP Research and Development ("R&D") and Selling, General and Administrative ("SG&A") expense (1) $175.0 - $195.0 (1) Refer to Non-GAAP Financial Measures section below for additional information.”
- “Non-GAAP combined R&D and SG&A expense guidance does not include stock-based compensation as we are currently unable to confidently estimate Full Year 2026 stock-based compensation expense.”
Quoted word-for-word from the SEC 8-K results press release.
KRYS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.92 | $2.16 | -11.3% | $126.5M | 10 |
| Next quarter (ends Dec 2026) | $2.01 | $2.33 | -13.6% | $134.3M | 10 |
| Current fiscal year (ends Dec 2026) | $7.59 | $8.21 | -7.5% | $496.7M | 11 |
| Next fiscal year (ends Dec 2027) | $8.95 | $9.87 | -9.3% | $634.2M | 11 |
KRYS options: expected move
Options price a move of about ±11.0% (±$35.35) by Nov 20, 2026, which includes earnings on Nov 2, 2026. Over the last 8 reports the stock moved ±7.3% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 49.1% | ±11.0% |
| Dec 18, 2026 | 56 | 46.0% | ±14.5% |
| Feb 19, 2027 | 119 | 48.5% | ±22.1% |
| Mar 19, 2027 | 147 | 50.8% | ±25.6% |
| May 21, 2027 | 210 | 50.6% | ±30.4% |
| Jun 17, 2027 | 237 | 49.2% | ±31.5% |
30-day implied volatility 49.2% vs 31.8% realized over the last 30 trading days. Put/call ratio (volume) 0.06. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:49 UTC)
| Price | USD 320.13 |
|---|---|
| Change | ▼ 0.63% (down) |
| Previous Close | USD 320.13 |
| Open | USD 320.13 |
| Day Range | USD 317.05 – 328.48 |
| 52-Week Range | USD 183.03 – 382.54 |
| Volume | 245,198 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (KRYS)
Nexqual's technical model rates KRYS "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:49 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.82 (neutral) |
| vs SMA50 | Below (USD 339.17) |
| MACD | -5.07 (negative) |
Earnings (KRYS)
| Next Earnings Date | 2026-11-02 |
|---|---|
| EPS Estimate | USD 1.92 |
| Revenue Estimate | $126.54M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.79 vs est 1.91 ▼ miss |
| 2026-03-31 | USD 1.83 vs est 1.42 ▲ beat |
| 2025-12-31 | USD 1.7 vs est 1.61 ▲ beat |
| 2025-09-30 | USD 2.66 vs est 1.12 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Financials & Fundamentals (KRYS)
| Total Revenue | $440.48M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +24.10% |
| Gross Margin | +94.64% |
| Operating Margin | +49.00% |
| Profit Margin | +54.82% |
| ROE | +20.12% |
| Debt / Equity | 0.01 |
| Current Ratio | 8.32 |
| Total Cash | $845.63M |
| Total Debt | $8.85M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $257.78M (58.5% of revenue) |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Financial Health Score (KRYS)
Nexqual rates Krystal Biotech, Inc.'s overall financial health "Strong" across five dimensions, as of October 23, 2026 at 09:49 UTC.
| Growth | Strong — Revenue +34% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 95%, operating 49% (last 12 months) |
| Balance Sheet | Strong — $846M cash vs $9M debt, net cash position |
| Cash Flow | Strong — FCF $258M (last 4 quarters to Jun 2026, SEC), 59% margin |
| Efficiency | Strong — ROE 20%, ROA 9.4% |
Ownership (KRYS)
| Insider Ownership | +10.66% |
|---|---|
| Institutional Ownership | +102.42% |
| Shares Outstanding | 29.60M |
| Float | 23.62M |
| Short % of Float | +19.23% |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
From Krystal Biotech, Inc.'s Latest SEC 10-K Filing (filed 2026-02-17)
Key Strengths & Strategy (as disclosed to the SEC)
- We believe that certain inherent features of the HSV-1 virus, combined with the modifications we have made to the viral backbone provides our proprietary gene therapy platform with specific advantages over other viral and non-viral vector platforms and represents an opportunity to generate a portfolio of highly differentiated and potentially first-in-class or best-in-class genetic medicines.
- KB408 is an inhaled (nebulized) formulation of our proprietary vector, designed to deliver two copies of the SERPINA1 transgene that encodes functional, full-length human AAT protein, for the treatment of AATD.
- In support of the Phase 2 study, we developed and validated a décolleté-specific photonumeric scale ("JDWS") which was submitted to the FDA in the second half of 2025.
- While our focus is on the development of gene therapies to treat patients with rare diseases with high unmet medical needs, we are also evaluating the potential of our platform to address more common severe or life-threatening diseases, such as non-small cell lung cancer ("NSCLC"), as well as aesthetic conditions via our wholly-owned subsidiary Jeune Aesthetics, Inc. ("Jeune Aesthetics"), which we incorporated in April 2019.
Legal & Regulatory Risks (Item 1A, quoted)
- We face significant competition in an environment of rapid technological change and the possibility that our competitors may achieve regulatory approval before us or develop therapies that are more advanced or effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize and market our product candidates.
- Our business operations may subject us to disputes, claims and lawsuits, which may be costly and time-consuming and could materially and adversely impact our financial position and results of operations.
- Our employees, principal investigators and advisors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
- We are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | USD 110.85 | ▼ 1.58% |
| PCVX | Vaxcyte, Inc. | USD 62.85 | ▼ 0.6% |
| PTGX | Protagonist Therapeutics, Inc. | USD 139.53 | ▲ 1.05% |
| TWST | Twist Bioscience Corporation | USD 135.47 | ▼ 9.16% |
| CAI | Caris Life Sciences, Inc. | USD 31.71 | ▼ 1.98% |
| IBRX | ImmunityBio, Inc. | USD 8.31 | ▼ 3.82% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:49 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt